Qiagen (NYSE:QGEN) Price Target Raised to $43.00 at Robert W. Baird

Qiagen (NYSE:QGEN - Get Free Report) had its price objective lifted by research analysts at Robert W. Baird from $42.00 to $43.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Robert W. Baird's price objective would suggest a potential upside of 2.14% from the company's previous close.

Several other brokerages have also issued reports on QGEN. Morgan Stanley reissued an "equal weight" rating and issued a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Baird R W downgraded Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group dropped their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Finally, Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $47.83.

Qiagen Trading Down 2.2 %

Shares of QGEN stock traded down $0.96 during mid-day trading on Monday, reaching $42.10. The stock had a trading volume of 896,194 shares, compared to its average volume of 1,141,015. Qiagen has a 52-week low of $37.63 and a 52-week high of $49.30. The firm has a market capitalization of $9.36 billion, a PE ratio of 117.23, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The stock's 50-day moving average price is $39.95 and its two-hundred day moving average price is $41.72.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Equities analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently modified their holdings of QGEN. Allspring Global Investments Holdings LLC boosted its position in Qiagen by 4.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock worth $96,605,000 after purchasing an additional 109,481 shares during the last quarter. Blue Trust Inc. increased its holdings in Qiagen by 30.5% during the first quarter. Blue Trust Inc. now owns 13,519 shares of the company's stock valued at $543,000 after buying an additional 3,157 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new position in Qiagen in the first quarter worth approximately $669,000. Exchange Traded Concepts LLC boosted its stake in shares of Qiagen by 2.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after acquiring an additional 395 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.